证券代码：600713 证券简称：南京医药 编号:ls2023-079 南京医药股份有限公司 关于 2023 年第三季度业绩说明会召开情况的公告 、 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京医药股份有限公司（以下简称"公司"）于2023年11月17日（星期五） 通过上海证券交易所上证路演中心线上召开了公司2023年第三季度业绩说明会， 现将具体情况公告如下： 一、本次业绩说明会召开情况简介 2023年11月9日，公司对外披露《南京医药股份有限公司关于召开2023年第 三季度业绩说明会的公告》（公告编号：ls2023-078）。公司于2023年11月17日 （星期五）下午15:00-16:30，通过上海证券交易所上证路演中心（网址：http://r oadshow.sseinfo.com/）以网络视频、图文展示及文字互动的方式召开了公司2023 年第三季度业绩说明会，公司董事长周建军先生，董事、总裁张靓先生，独立董 事胡志刚先生，副总裁、董事会秘书李文骏先生，总会计师孙剑先生出席了本次 会议，会议由李文骏先生主持，周 ...

证券代码：600713 证券简称：南京医药 编号：ls2023-078 南京医药股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ● 会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow.sseinfo.co m/） ● 会议召开方式：上证路演中心网络视频、图文展示及文字互动 ● 投资者可于2023年11月10日（星期五）至11月16日（星期四）16:00前登录上证 路演中心网站首页点击"提问预征集"栏目或通过公司邮箱600713@njyy.com进行提问。 公司将在说明会上对投资者普遍关注的问题进行回答。 南京医药股份有限公司（以下简称"公司"）已于2023年10月31日发布了2023年 第三季度报告，为便于广大投资者更全面深入地了解公司2023年第三季度的经营成果、 财务状况，公司计划于2023年11月17日下午15:00-16:30举行2023年第三季度业绩说明 会，就投资者关心的问题进行交流。 一、说明会类型 本次业绩说明会以网络互动 ...

证券代码：600713 证券简称：南京医药 编号:ls2023-075 南京医药股份有限公司 2023 年度第三期超短期融资券兑付公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本期债券基本情况 为保证南京医药股份有限公司 2023 年度第三期超短期融资券（债券简称： 23 南京医药 SCP003，债券代码：012380641）兑付工作的顺利进行，现将有关事 宜公告如下： 16、登记托管机构：银行间市场清算所股份有限公司 二、兑付相关事宜 托管在银行间市场清算所股份有限公司的债券，其兑付资金由发行人在规定 时间之前划付至银行间市场清算所股份有限公司指定的收款账户后，由银行间市 场清算所股份有限公司在兑付日划付至债券持有人指定的银行账户。债券兑付日 如遇法定节假日，则划付资金的时间相应顺延。债券持有人资金汇划路径变更， 应在兑付前将新的资金汇划路径及时通知银行间市场清算所股份有限公司。因债 券持有人资金汇划路径变更未及时通知银行间市场清算所股份有限公司而不能 及时收到资金的，发行人及银行间市场清算所股份有限公司不承担由 ...

一、本期债券基本情况 为保证南京医药股份有限公司 2023 年度第七期超短期融资券（债券简称： 23 南京医药 SCP007，债券代码：012381879）兑付工作的顺利进行，现将有关事 宜公告如下： 证券代码：600713 证券简称：南京医药 编号:ls2023-076 南京医药股份有限公司 2023 年度第七期超短期融资券兑付公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 16、登记托管机构：银行间市场清算所股份有限公司 二、兑付相关事宜 托管在银行间市场清算所股份有限公司的债券，其兑付资金由发行人在规定 时间之前划付至银行间市场清算所股份有限公司指定的收款账户后，由银行间市 场清算所股份有限公司在兑付日划付至债券持有人指定的银行账户。债券兑付日 如遇法定节假日，则划付资金的时间相应顺延。债券持有人资金汇划路径变更， 应在兑付前将新的资金汇划路径及时通知银行间市场清算所股份有限公司。因债 券持有人资金汇划路径变更未及时通知银行间市场清算所股份有限公司而不能 及时收到资金的，发行人及银行间市场清算所股份有限公司不承担由 ...

证券代码：600713 证券简称：南京医药 编号:ls2023-077 南京医药股份有限公司 2023 年度第八期超短期融资券兑付公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本期债券基本情况 二、兑付相关事宜 托管在银行间市场清算所股份有限公司的债券，其兑付资金由发行人在规定 时间之前划付至银行间市场清算所股份有限公司指定的收款账户后，由银行间市 场清算所股份有限公司在兑付日划付至债券持有人指定的银行账户。债券兑付日 如遇法定节假日，则划付资金的时间相应顺延。债券持有人资金汇划路径变更， 应在兑付前将新的资金汇划路径及时通知银行间市场清算所股份有限公司。因债 券持有人资金汇划路径变更未及时通知银行间市场清算所股份有限公司而不能 及时收到资金的，发行人及银行间市场清算所股份有限公司不承担由此产生的任 何损失。 三、相关机构联系人和联系方式 1 2、债项名称：南京医药股份有限公司 2023 年度第八期超短期融资券 3、债项简称：23 南京医药 SCP008 4、债项代码：012381903 5、发行金额：人民币 5 ...

Financial Performance - The company's operating revenue for Q3 2023 was CNY 13,203,658,118.16, a decrease of 2.16% compared to the same period last year[4] - The net profit attributable to shareholders was CNY 131,653,503.45, down 3.92% year-on-year[4] - The basic earnings per share for the quarter was CNY 0.10, reflecting a decline of 7.27% compared to the previous year[4] - Total operating revenue for the first three quarters of 2023 reached ¥40.55 billion, an increase of 8.3% compared to ¥37.44 billion in the same period of 2022[35] - Net profit for the first three quarters of 2023 was ¥532.96 million, a decrease of 4.1% from ¥555.61 million in the same period of 2022[36] - The basic earnings per share for the first three quarters of 2023 was ¥0.34, down from ¥0.38 in the same period of 2022[37] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 33,202,829,130.69, an increase of 4.90% from the end of the previous year[4] - The total assets as of September 30, 2023, amounted to ¥20,655,438,149.64, compared to ¥17,887,960,122.52 at the end of 2022, indicating an increase of 15.5%[43] - The total liabilities of the company as of the end of the third quarter of 2023 amounted to ¥26.14 billion, an increase from ¥24.96 billion at the end of 2022[36] - The total liabilities increased to ¥15,425,338,619.69 as of September 30, 2023, from ¥12,855,143,912.17 at the end of 2022, marking a rise of 20.5%[43] Cash Flow - The cash flow from operating activities showed a significant decrease due to an increase in accounts receivable[7] - The company's cash flow from operating activities showed a net outflow of ¥4.48 billion in the first three quarters of 2023, compared to a net outflow of ¥3.21 billion in 2022[38] - The cash inflow from operating activities totaled ¥40.96 billion in the first three quarters of 2023, compared to ¥34.92 billion in 2022, indicating a growth of 17.5%[38] - The net cash flow from operating activities was negative at approximately -¥821.53 million, worsening from -¥687.11 million year-on-year[47] Shareholder Information - The company has a total of 61,552 ordinary shareholders as of the reporting period[9] - The company reported a total equity attributable to shareholders of CNY 6,291,889,649.71, up 4.87% from the previous year[4] - The company's total equity reached ¥7.07 billion by the end of the third quarter of 2023, compared to ¥6.69 billion at the end of 2022, reflecting a growth of 5.6%[36] - The total equity of the company as of September 30, 2023, was ¥5,230,099,529.95, up from ¥5,032,816,210.35 at the end of 2022, indicating a growth of 3.93%[43] Investments and Projects - The company plans to raise up to CNY 1,081.49 million through convertible bonds, with key projects including digital transformation and logistics center expansion[11] - The company has approved a total R&D budget of CNY 3,062 million for multiple projects, with Nanjing Pharmaceutical responsible for CNY 2,725.60 million[25] - The company is investing up to CNY 149.63 million in the construction of the Nanjing Pharmaceutical Central Logistics Integration Project[28] - Nanjing Pharmaceutical has completed the acquisition of 100% equity in Hubei Kaipute Pharmaceutical Co., Ltd. for CNY 0.32 million, with a subsequent capital increase of CNY 6.90 million[26] Research and Development - Research and development expenses increased to ¥28.51 million in 2023 from ¥21.89 million in 2022, marking a rise of 30.3%[36] - The company's R&D expenses for the first three quarters of 2023 were ¥6,771,698.11, slightly higher than ¥6,386,980.48 in the same period of 2022[44] Market Strategy - The company plans to continue expanding its market presence and investing in new technologies and products to drive future growth[49] - The company has implemented new accounting standards starting in 2023, which may affect the financial reporting and analysis going forward[48]

证券代码：600713 证券简称：南京医药 编号:ls2023-074 南京医药股份有限公司 关于 2023 年半年度业绩说明会召开情况的公告 、 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京医药股份有限公司（以下简称"公司"）于2023年9月13日（星期三） 通过上海证券交易所上证路演中心线上召开了公司2023年半年度业绩说明会，现 将具体情况公告如下： 一、本次业绩说明会召开情况简介 答：感谢您对公司的关注！公司的国有控股股东是南京新工投资集团有限责 任公司，是南京市国资委控股企业、国有资本投资公司。今年5月中旬，新工集 团新入选国务院国资委"双百企业"名单。 根据新工集团官方网站介绍，其肩负推进先进制造业和战略性新兴产业发展， 对重大产业发展项目融资并进行先导性投资的重任；承担市属国有工业企业的经 营管理、资产保值增值及维护稳定的重要任务。截至2022年末，新工集团资产总 1 额为869.42亿元，净资产 372.34亿元。2022年完成营业收入608.2亿元，实 现利润总额21.3亿元。该集团位列"2022中国 ...

证券代码：600713 证券简称：南京医药 编号：ls2023-073 南京医药股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 会议召开时间：2023年9月13日（星期三）上午 10:00-11:30 ● 会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow.sseinfo.co m/） ● 会议召开方式：上证路演中心网络视频、图文展示及文字互动 ● 投资者可于2023年9月6日（星期三）至9月12日（星期二）16:00前登录上证路演 中心网站首页点击"提问预征集"栏目或通过公司邮箱600713@njyy.com进行提问。公 司将在说明会上对投资者普遍关注的问题进行回答。 南京医药股份有限公司（以下简称"公司"）已于2023年8月31日发布了2023年半 年度报告，为便于广大投资者更全面深入地了解公司2023年半年度的经营成果、财务 状况，公司计划于2023年9月13日上午10:00-11:30举行2023年半年度业绩说明 ...

证券代码：600713 证券简称：南京医药 编号:ls2023-072 南京医药股份有限公司关于公司 参与投资设立私募股权投资基金暨签订合伙协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 南京医药股份有限公司（以下简称"公司"或"南京医药"）与南京新工新兴产 业投资管理有限公司（以下简称"新工产投"）、南京新工投资集团有限责任公司（以下 简称"新工投资集团"）、南京江宁高新区科技创业投资管理有限公司（以下简称"江宁 高新创投"）、南京江宁产业发展基金有限责任公司（以下简称"江宁产业发展基金"）、 南京江宁天印壹号股权投资合伙企业（有限合伙）（以下简称"江宁天印壹号基金"）正 式签订合伙协议，将共同出资 2 亿元（人民币，下同）设立南京新工医疗健康产业投资 合伙企业（有限合伙）（以下简称"本基金、合伙企业"）。 新工投资集团为公司控股股东，直接持有公司 44.13%股权，新工产投为新工投 资集团全资子公司，根据《上海证券交易所股票上市规则》6.3.3 的规定，新工投资集 团、新工产投为公司关联法人，本 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥27,343,124,491.26, representing a 14.21% increase compared to ¥23,940,993,596.60 in the same period last year[19]. - The total profit for the period was ¥521,521,181.46, up 13.01% from ¥461,468,360.84 in the previous year[19]. - The net profit attributable to shareholders decreased by 7.38% to ¥308,641,881.41 from ¥333,218,365.52 year-on-year[19]. - The net cash flow from operating activities was negative at -¥2,721,066,361.61, compared to -¥2,390,346,586.26 in the previous year[19]. - Basic earnings per share decreased by 14.13% to ¥0.237 from ¥0.276 in the same period last year[20]. - The weighted average return on net assets fell to 5.007% from 6.149%, a decrease of 1.142 percentage points[20]. - The company's operating revenue increased by 14.21% to CNY 27,343.12 million, while operating costs rose by 14.84% to CNY 25,706.23 million[49]. - The net profit after deducting non-recurring gains and losses for the first half of 2023 was approximately ¥300 million, a decrease of 7.38% compared to the same period last year[140]. - The total comprehensive income for the first half of 2023 was ¥114,066,198.01, down from ¥162,690,412.98 in the same period last year[152]. Assets and Liabilities - The total assets of the company increased by 5.44% to ¥33,371,894,066.38 from ¥31,650,959,639.82 at the end of the previous year[19]. - The total liabilities reached ¥26.43 billion, up from ¥24.96 billion at the end of the previous year[145]. - The company's total equity increased to approximately ¥6.94 billion from ¥6.69 billion at the end of the previous year[145]. - The debt-to-asset ratio was 79.20%, slightly up from 78.85% at the end of the previous year[140]. - The current ratio improved to 1.37, up 4.58% from 1.31 at the end of the previous year[140]. - Short-term borrowings increased significantly to ¥4.30 billion from ¥1.80 billion at the end of the previous year[145]. - The company's total liabilities as of June 30, 2023, were ¥14.60 billion, an increase from ¥12.86 billion at the end of 2022, representing a growth of 13.5%[147]. Cash Flow - The cash flow from operating activities showed a net outflow of ¥2,721,066,361.61, compared to a net outflow of ¥2,390,346,586.26 in the first half of 2022[155]. - Cash and cash equivalents decreased to approximately ¥2.01 billion from ¥2.33 billion at the end of 2022[144]. - The company raised ¥12,326,769,660.05 in borrowings during the first half of 2023, compared to ¥12,557,214,316.64 in the same period of 2022[155]. - The company’s investment activities resulted in a net cash outflow of ¥46,203,076.68 in the first half of 2023, contrasting with a net inflow of ¥1,566,033.68 in the same period of 2022[155]. Business Operations - The company operates 604 retail stores, including 11 regional brand chain institutions[30]. - The company is focusing on digitalization and modern supply chain system construction to enhance operational efficiency[26]. - The company is expanding its business into "Internet+" healthcare services and third-party logistics[27]. - The company aims to strengthen its core competitiveness while adapting to external environmental changes[26]. - The company is exploring multi-modal pharmaceutical retail business and enhancing pharmacy service levels[30]. - The company operates 163 specialized pharmacies, expanding its DTP pharmacy business and enhancing resource collaboration in the prescription market[31]. Research and Development - Research and development expenses increased by 32.68% to CNY 17.90 million, reflecting a commitment to enhancing information technology development[49]. - The company introduced 35 new drug varieties over the past three years, achieving a new drug sales growth of 635.06% with a new drug introduction rate of 86.18%[45]. - The company incurred research and development expenses of ¥5,171,698.11 in the first half of 2023, up from ¥3,732,279.28 in the previous year, reflecting a focus on innovation[152]. Risk Management - There were no significant risk events reported during the period, and the company has outlined potential risks in the management discussion section[6]. - The company is facing risks from prolonged payment terms from public medical institutions, which may affect cash flow efficiency[72]. - The company has established a comprehensive risk management framework to support its operational and strategic objectives[79]. Corporate Governance - The company aims to enhance its governance structure and market-oriented mechanisms as part of its "first-class enterprise" initiative from 2022 to 2025[43]. - A new internal audit management system was established to enhance risk control and internal supervision, approved by the board in early 2023[79]. - The company is focusing on strengthening its internal audit system and has revised its internal audit regulations to ensure compliance and effectiveness[79]. Shareholder Information - The total number of ordinary shareholders reached 58,523 by the end of the reporting period[125]. - The largest shareholder, Nanjing New Industry Investment Group, holds 44.13% of the shares, totaling 578,207,286 shares[127]. - The company completed the repurchase and cancellation of 84,000 restricted shares under the 2021 incentive plan, reducing the total share capital to 1,310,231,012 shares[121]. Financing Activities - The company plans to issue convertible bonds to raise up to CNY 1,081.49 million for digital transformation and logistics projects, enhancing core competitiveness[43]. - Nanjing Pharmaceutical Co., Ltd. issued a total of 500 million yuan in short-term financing bonds with interest rates ranging from 2.27% to 2.77% across different tranches[136]. - The total bond issuance for the year 2023 is projected to reach 4 billion yuan, aimed at supporting operational and expansion activities[136]. Market Position - The company ranks sixth in the domestic pharmaceutical circulation industry in terms of business scale as of 2022[27]. - The total sales of the national pharmaceutical circulation market reached 2,751.6 billion yuan, with a year-on-year growth of 6.0%, a slowdown of 2.5 percentage points[25]. - The retail market sales amounted to 599.0 billion yuan, with a year-on-year growth of 10.7%, accelerating by 3.3 percentage points[26].